TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB announced its participation in the Redeye Technology & Life Science Day 2025, where CEO Kristina Torfgård and EVP Nicholas Waters will present and engage in a Q&A session. This event highlights IRLAB’s active engagement in the scientific community and provides a platform to showcase its advancements in Parkinson’s disease treatments, potentially strengthening its industry position and stakeholder relations.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing innovative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing a portfolio of treatments, including Mesdopetam for levodopa-induced dyskinesias, Pirepemat for fall frequency, and IRL757 for apathy in neurodegenerative disorders. Their research is driven by the proprietary Integrative Screening Process (ISP) platform.
Average Trading Volume: 250,286
Technical Sentiment Signal: Sell
Current Market Cap: SEK166.1M
See more data about IRLAB.A stock on TipRanks’ Stock Analysis page.